A share price of Celldex Therapeutics Inc [CLDX] is currently trading at $25.38, up 2.26%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLDX shares have lost -4.05% over the last week, with a monthly amount glided 1.60%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Celldex Therapeutics Inc [NASDAQ: CLDX] stock has seen the most recent analyst activity on October 07, 2024, when Citigroup initiated its Buy rating and assigned the stock a price target of $70. Previously, Goldman started tracking the stock with Neutral rating on September 30, 2024, and set its price target to $45. On September 27, 2024, downgrade downgraded it’s rating to Peer Perform. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $58 on June 18, 2024. Wolfe Research initiated its recommendation with a Outperform and recommended $51 as its price target on June 11, 2024. In a note dated November 10, 2023, Wells Fargo upgraded an Equal Weight rating on this stock but restated the target price of $27.
Celldex Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $22.93 and $53.18. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Celldex Therapeutics Inc [NASDAQ: CLDX] shares were valued at $25.38 at the most recent close of the market. An investor can expect a potential return of 144.29% based on the average CLDX price forecast.
Analyzing the CLDX fundamentals
Trailing Twelve Months sales for Celldex Therapeutics Inc [NASDAQ:CLDX] were 9.98M which represents 110.35% growth. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at -17.46%, Pretax Profit Margin comes in at -15.44%, and Net Profit Margin reading is -15.44%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.21 and Total Capital is -0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 24.39 points at the first support level, and at 23.41 for the second support level. However, for the 1st resistance point, the stock is sitting at 25.91, and for the 2nd resistance point, it is at 26.45.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Celldex Therapeutics Inc [NASDAQ:CLDX] is 24.27. Further, the Quick Ratio stands at 24.27, while the Cash Ratio is 1.13. Considering the valuation of this stock, the price to sales ratio is 168.72, the price to book ratio is 2.14.
Transactions by insiders
Recent insider trading involved Marucci Anthony S, PRESIDENT & CEO, that happened on Nov 11 ’24 when 11500.0 shares were purchased. SVP AND CFO, Martin Samuel Bates completed a deal on Jun 14 ’24 to sell 17172.0 shares. Meanwhile, SR. VP & CPDO Crowley Elizabeth sold 30000.0 shares on Jun 14 ’24.
